Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Eckuity Capital Launches Fund II and Backs Automata Technologies

By: Eckuity Capital via Business Wire

June 25, 2026 at 12:45 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Fund II reaches first close and is already deploying capital
Fund II leads Automata Technologies’ Series C, alongside global science and technology leader Danaher
Fund II builds on a first fund fully deployed across 14 high growth life sciences companies

Eckuity Capital, a North American healthcare growth equity firm, today announced the first close of Eckuity Capital Fund II and the fund’s inaugural investment, leading the Series C of Automata Technologies alongside Danaher, a global science and technology leader.

Automata uses artificial intelligence to automate laboratory operations for life sciences and diagnostics organisations, work that has long been manual, slow, and hard to scale. Backing from Eckuity and Danaher places the company at the center of how artificial intelligence is changing scientific work.

Eckuity Capital Fund II extends a strategy proven in Eckuity’s first fund, which is fully deployed across 14 companies, investing in commercial-stage life sciences companies and combining capital with the commercial support to scale them. With its first close complete and capital already at work, Eckuity will keep building the Fund II portfolio through the year.

Eckuity has also strengthened its investment team, welcoming Paul Enever and Alejandro Sanchez as Partners. Enever, a former McKinsey partner with 25 years in medical technology, serves on several boards including GT Medical Technologies and Magnolia Medical Technologies, with past exits including Cardiva Medical to Haemonetics. Sanchez, a former McKinsey partner and co-founder of Hermes Growth Partners, sits on the board of PreludeDx, with past exits including Biotheranostics to Hologic.

“Healthcare will change more in the next decade than it has in a generation, and the firms that matter will be the ones turning artificial intelligence into tools clinicians and scientists actually use,” said Youssef Sebban, Founder and Managing Partner of Eckuity Capital. “We built Eckuity to back those companies at the commercial stage, where the change becomes real. Opening Fund II with our first investment in Automata, alongside Danaher, is the standard we intend to set. And we are only getting started.”

“Automating the lab is one of the highest-leverage problems in science, and solving it takes partners who understand both the technology and the path to commercial scale,” said Mostafa ElSayed, CEO of Automata Technologies. “Eckuity led our Series C because they understood exactly what we are building. With Eckuity and Danaher behind us, we can bring AI into the lab at a pace the field has not seen.”

About Eckuity Capital

Eckuity Capital is a healthcare growth equity firm investing in commercial-stage companies across North America and Western Europe, spanning medical technology, diagnostics, and tech-enabled healthcare services. Beyond capital, the firm provides the commercial support its companies need to scale. Founded in 2021, Eckuity operates from New York, London, and Miami. For more information, visit www.eckuity.com.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any security or interest in any fund managed by Eckuity Capital. Any such offer will be made only through definitive offering documents and to eligible investors. Statements regarding future events or expectations are forward-looking and subject to risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260625424100/en/

Contacts

Media Contact
Eckuity Capital
Ryan Green, Head of Capital Formation and Investor Relations
ryan.green@eckuity.com | +1 (973) 229-7859

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	227.58	-6.69 (-2.86%)
AAPL	275.97	-17.11 (-5.84%)
AMD	525.97	+6.23 (1.20%)
BAC	58.09	+0.36 (0.62%)
GOOG	339.93	-5.11 (-1.48%)
META	543.52	-14.15 (-2.54%)
MSFT	354.35	-11.11 (-3.04%)
NVDA	194.33	-4.67 (-2.35%)
ORCL	152.32	-5.21 (-3.31%)
TSLA	374.28	-1.25 (-0.33%)